companies / pathiostherapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 25,272,00025.3M | ○ |
|---|---|---|
| founded | 2018 | |
| hq | Oxford, UK | |
| industry | unknown | |
| stage | series-b+ |
Pathios Therapeutics is a clinical-stage oncology and immunology company targeting GPR65, an acid-sensing receptor on immune cells. It serves patients with solid tumors who could benefit from a new immunotherapy. It inhibits GPR65 to fix immune dysfunction in the acidic tumor microenvironment.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-04-01 | series-b | 25,272,00025.3M | null | ○ |
WordPress 6.9.4, Modernizr, Yoast SEO 27.5, reCAPTCHA, Google Analytics, Google Hosted Libraries, Google Maps, Google Tag Manager, Flywheel 5.1.0, DoubleClick Floodlight, Contact Form 7 6.1.5, CookieYes 3.4.2
| fact | status | src |
|---|---|---|
| Series B, $25.3M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |